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Background 
By far the most challenging tasks in assuring the quality and safety of pharmaceutical products and 
the delivery of effective healthcare to patients are to detect adulterated, fake, unregulated, and/or 
poor quality medicines, also termed as “falsified medicines”, and to prevent their distribution. 
Falsified medicines are endemic in the global drug supply chain, including traditional distribution 
settings, unregulated sectors, and on the internet. Additionally, substandard medicines, which are 
produced by legitimate manufacturers but fail to meet basic quality control tests, pose another risk to 
patients’ health. At best, these poor quality medicines are ineffective; at worst, they result in death. 
These life-threatening medicines are on the rise in both therapeutic and geographic scope, 
threatening patients’ lives, and profiting organized criminal actors involving illicit medicines. Yet, 
despite these clear threats, surveillance is extremely limited, with available data pointing to an 
increasing global health crisis worldwide that is yet to be addressed. 
Objectives 
The aim of this study was to investigate the situation of substandard and falsified medicines and the 
threat they pose to public health. The quality of two lifestyle medicines – omeprazole and 
pioglitazone – was examined in samples collected during surveys in Cambodia and Myanmar, and in 
addition a study of the public health consequences of falsified medicines was carried out based on 
evidence collected from the literature. 
Erroneous formulation of delayed-release omeprazole capsules: Alert for importing countries  
In 2014, quality assessment of omeprazole samples collected from Myanmar showed high failure 
rates in pharmacopoeial tests, especially in dissolution tests. The results indicated a high prevalence 
of substandard omeprazole in the country, and possible causes were investigated by means of 
detailed evaluation. For this purpose we conducted pharmacopoeial quantity, content uniformity and 
dissolution tests of 156 samples of omeprazole capsules collected in Cambodia in 2010 and Myanmar 
in 2014 (Table 1). High failure rates were found, especially in dissolution testing, and detailed 
investigation of several unacceptable samples was carried out by means of in-vitro dissolution 
profiling, scanning electron microscopy (SEM) and X-ray computed tomography (X-ray CT) to 
identify the cause of failure. 
Dissolution profiling with and without the acid stage showed that acid caused premature omeprazole 
release, indicating that the enteric coating of the omeprazole granules was ineffective. SEM 
examination of two failed samples revealed cracked and broken granules mixed with apparently intact 
omeprazole granules in the capsule. X-ray CT examination indicated that some granules of failed 
samples completely lacked enteric coating, and others had incomplete and non-uniform enteric coating 
or malformation. 
In conclusion, omeprazole capsules collected in Myanmar and Cambodia showed high failure rates in 
pharmacopoeial tests, especially dissolution tests. Some samples were found to have ineffective or 
absent enteric coating of the granules, resulting in premature dissolution and degradation in acidic 
conditions. This is a potentially serious public health issue that needs to be addressed by regulatory 
authorities in Cambodia and Myanmar, possibly through a collaborative initiative with manufacturers. 
Table 1: Outline of the samples and the summary of the quality test results for omeprazole 
















n/% n/% n/% 
Cambodia 
2010 
(n = 91) 
Pharmacy 26/28.5 
2/2.2 89/97.8 
Quantity 54/59.3 22/24.2 15/16.5 
Depot 45/49.5 Content 
Uniformity 
31/34.1 14/15.4 46/50.5 
Wholesaler 8/8.8 
Outlet 12/13.2 Dissolution 42/46.2 45/49.4 4/4.4 
Myanmar 
2014 
(n = 65) 
Pharmacy 35/53.8 
0/0 65/100 




56/86.2 9/13.8 0/0 
Wholesaler 4/6.2 Dissolution 48/73.8 17/26.2 0/0 
	
 
*insufficient material available for full testing 
 
Quality of omeprazole purchased via the internet and personally imported into Japan: 
Comparison with products sampled in other Asian countries 
Further evaluation of the quality of omeprazole purchased from internet sources and personally 
imported into Japan showed variations in the quality of the same product from the same 
manufacturer distributed in developing and developed countries, by comparing personal import 
samples with the products previously collected during the surveys in Cambodia and Myanmar. 
For this study we evaluated the quality of omeprazole purchased via the internet and personally 
imported into Japan. We also compared the quality of these samples with that of the same products 
from the same manufacturers previously collected in surveys in two other Asian countries.  
The personally imported omeprazole samples, which originated from 17 different manufacturers in 6 
countries, were evaluated by observation, authenticity investigation, and pharmacopoeial quality 
analysis. Among the 28 samples analyzed, 26 (92.9 %) have passed in quantity and content 
uniformity tests, and all the samples have passed in the dissolution test (Table 2). Dissolution 
profiling confirmed that all the personally imported omeprazole samples remained intact in the acid 
stage. On the other hand, samples from some of the same manufacturers, previously collected during 
surveys in Cambodia and Myanmar, frequently showed premature omeprazole release in acid. 
Raman spectroscopy and principal component analysis (PCA) showed significant variation between 
omeprazole formulations in personally imported samples and the samples from Cambodia and 
Myanmar. Thus, our results indicate that omeprazole formulations distributed in different market 
segments by the same manufacturers were of diverse quality. Measures are needed to ensure 
consistent quality product, and to prevent entry of substandard products into the legitimate supply 
chain. 
Table 2: Quality test results of omeprazole personally imported into Japan 






















Public health concerns of substandard antidiabetic medicine: Quality estimation of 
pioglitazone by a cross-sectional survey 
Quality assessment of pioglitazone collected in China, Myanmar and purchased from internet 
sources revealed similar quality problems, although most of the pioglitazone samples collected from 
Shanghai, China were satisfactory. In terms of quality, most of the unsatisfactory samples failed in 
the dissolution test. The results of this study result suggest that continued monitoring is necessary 
particularly in Myanmar, Cambodia and for personal import medicines. 
Between 2012 and 2015 a cross-sectional investigation was conducted to study the quality of 
pioglitazone. A total of 163 samples were collected for this study. Among these, n=44 samples were 
from Shanghai, China, n=60 sample from Mandalay, Myanmar and n=59 samples were from internet 
sources and personally imported samples to Japan. The details of the sample location and number of 
samples along with their strength are outlined in Table 3. 
Collected samples were then analyzed by visual inspection, authenticity investigation, and 
pharmacopoeial analysis by high-performance liquid chromatography. Although no packaging defect 
or suspicious information was found from the visual inspection, minimum response was found from 
the manufacturer during authenticity investigation. 
After the final assessment, quality test results of the sample from Shanghai were found satisfactory 
where only 1 sample failed to meet the pharmacopoeial requirement. The average quantity of API 
(active pharmaceutical ingredient) in all the samples was 98.1%±2.7 (mean±SD) of label claim and 
the acceptance value (AV) for uniformity of content of all samples was below 15. However, in the 
case of samples from Myanmar and personal import, dissolution of the pioglitazone tablet in the 
dissolution medium was the main concern. For personal import, 38% generic samples were found to 
be failed among the 13 samples analyzed. In Myanmar 2015, among the collected 60 samples 13.3% 
samples were found to be failed. For imported and Myanmar pioglitazone samples, dissolution was 
the main problem where the tablets failed repeatedly to disintegrate and dissolve in the medium 
indicating the solubility problem. For personally imported pioglitazone from online sites, 
substandard pioglitazone amounted up to 8.5% of total sample collected. 3 personally imported 
samples failed seriously in dissolution test, drug release amount of which was below 30%. For 
Myanmar sample the failure rate was even higher than the personal import samples, which was 
13.3%. The dissolution profile of these failed samples indicated that they need much longer time to 
dissolve properly in the medium. While the sample were crushed into powder form and allowed in 
the medium, percent dissolution was higher than the tablet. 
In contempt of the apparent satisfaction about the quality of pioglitazone samples collected from 
China, substandard pioglitazone from internet and Myanmar was the key issue. The substandard 
antidiabetic medicine that would not have had any antidiabetic effect would have been a waste of 
patient’s money. The internet pharmacies those are selling pioglitazone online without restriction and 
approval is also of great concern. 
 
Table 3: Outline of the samples by sampling site, category and strength 
Sampling Site Year Category 
Strength 
15 mg 30 mg 45 mg  
Shanghai, China (Chang, 2014) 2012 
Brand 9 - - 
44 
Generic 35 - - 
Personal import samples 2013 
Brand 19 4 5 
59 
Generic 19 9 3 
Mandalay, Myanmar 2015 
Brand 1 - - 
60 
Generic 59 - - 
Total number of samples N=163 
 
The health consequences of falsified medicines: A study of the published literature 
To investigate the health consequences of falsified medicines for patients, a study of the literature 
was carried out to identify published papers dealing with this issue. Data were collected on the 
mortality and morbidity of the populations exposed to falsified medicines, focusing on the scale of 
the issue, the geographic extent, the medicines affected, and the harm caused. The study indicates 
that falsified medicines have impacted substantially on public health worldwide, and also suggests 
that developed and developing countries are almost equally affected. 
For this study we searched PubMed for articles dealing with the health cost of falsified medicines, 
focusing on their consequences for mortality and morbidity, as well as the scale of the issue, the 
geographic extent, the medicines affected, and the harm caused, using pre-optimized keywords 
"(counterfeit OR fake OR bogus OR falsified OR spurious) AND (medicine OR drug)".Searches up 
to February 2017 yielded 2006 hits, of which 1791 were full-length articles in English. Among them, 
we found 81 papers that qualitatively or quantitatively described 48 incidents in which falsified 
medicines caused patients to suffer serious adverse effects, injury, symptoms or death. 
The distribution of incidents were examined according to the economic status of the countries 
involved, regional location in the world, therapeutic category of the medicines, number of incidents 
by year, number of victims by year, and characteristics of the falsified medicines. Among the 48 
reported incidents, 27 (56.3%) occurred in developing countries and 21 (43.7%) in developed 
countries. Theseincidents involved a total of 7200 casualties including 3604 deaths(death rate 
50.1%). 
The results indicate that all types of medications have been targeted for falsification, and falsified 
medicines have had a serious impact on the health of both adults and children worldwide, with 
similar numbers of incidents in developing and developed countries. 
The results of the present studies have enhanced our understanding of the scope of the problem of 
falsified and substandard medicines, and led to several important conclusions. The problem of poor 
and variable drug quality is identified as a major public health challenge. It can lead to the 
therapeutic failure, loss of lives, and loss of trust in the health system. Moreover, online sites selling 
medicines for personal use pose a substantial risk to drug quality. To eliminate the problem of poor 
drug quality and ensure access of people to safe and effective medicines, it will be necessary for all 
stakeholders to work together in undertaking a comprehensive assessment of the quality of medicines 
accessed locally and/or internationally, and also to develop effective regulatory controls to prevent 
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